Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN U F versus NYSTAFORM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN U F versus NYSTAFORM.
FULVICIN-U/F vs NYSTAFORM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of fungal cell mitosis by binding to microtubules, disrupting spindle formation and nuclear division.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
125 mg orally once daily with a high-fat meal for 7 days, then 125 mg every other day for 7 days (total 13 doses).
1 tablet (nystatin 100,000 units) orally three times daily after meals. Each tablet should be allowed to dissolve slowly in the mouth.
None Documented
None Documented
Terminal half-life approximately 9.5 hours; may be prolonged in liver disease.
Plasma half-life is not measurable due to negligible systemic absorption. Topical or oral administration results in local action only; no systemic half-life is clinically relevant.
Primarily hepatic metabolism; <1% excreted unchanged in urine; metabolites excreted in bile and feces.
Nystatin is not absorbed from the gastrointestinal tract, intact skin, or mucous membranes. After oral administration, it is excreted almost entirely unchanged in feces (over 99%). Minimal renal excretion occurs (less than 1%).
Category C
Category C
Antifungal
Antifungal